10-K: Milestone Pharmaceuticals Inc. Reports 2024 Results, Awaits FDA Decision on CARDAMYST

Milestone Pharmaceuticals Inc. announces its 2024 financial results and awaits the FDA's decision on CARDAMYST for PSVT, expected by March 27, 2025.

Summary

• Milestone Pharmaceuticals Inc. is focused on developing and commercializing cardiovascular medicines.
• The company is awaiting FDA approval for CARDAMYST (etripamil) for the treatment of paroxysmal supraventricular tachycardia (PSVT), with a decision expected by March 27, 2025.
• Milestone is also developing etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR).
• A Phase 3 study for AFib-RVR is planned, with patient enrollment anticipated in 2025.
• The company estimates the immediate target addressable market for CARDAMYST as approximately 60% of patients who are actively managed by clinical cardiologists, interventional cardiologists and electrophysiologists.
• Cardiologists reported a willingness to prescribe CARDAMYST to approximately 50% of the patients with PSVT in their care, which suggests approximately 500,000 to 800,000 patients can potentially be treated with CARDAMYST in peak years.
• This implies a peak demand potential in the United States for CARDAMYST of 2.5 million to 4 million episodes treated per year.
• The company incurred a net loss of $41.5 million in 2024, compared to a net loss of $59.7 million in 2023.
• As of December 31, 2024, Milestone had cash, cash equivalents, and short-term investments totaling $69.7 million.
• The company believes its current funds will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there's progress in clinical trials and a potential market opportunity, the company is still operating at a loss and requires additional funding.

Positives

• FDA acceptance of the New Drug Application (NDA) for CARDAMYST.
• Positive Phase 2 data from the ReVeRA study for AFib-RVR.
• Planned Phase 3 study for AFib-RVR with patient enrollment anticipated in 2025.
• Positive topline data from the Phase 3 JX02002 clinical trial of etripamil nasal spray in patients with PSVT in China by licensing partner, Corxel.
• Reduction in net loss from $59.7 million in 2023 to $41.5 million in 2024.
• New Method of Use patent for etripamil nasal spray potentially extends intellectual property protection in the United States until July 2042.

Negatives

• The company has incurred significant operating losses since inception and anticipates continuing to incur substantial operating losses for the foreseeable future.
• The company has only one product candidate, etripamil, for which it is currently pursuing clinical development and regulatory approval.
• The market price of the company's common shares has been and may continue to be volatile and fluctuate substantially.

Risks

• The company will require substantial additional funding to finance its operations.
• The company's future success is substantially dependent on the successful clinical development and regulatory approval of etripamil.
• The company may encounter substantial delays or difficulties in its clinical trials.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside the company's control.
• If the company is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell etripamil or any future product candidates, it may not be successful in commercializing etripamil or any future product candidates, if and when they are approved.
• Even if etripamil or any future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third party payors or others in the medical community necessary for commercial success.
• If the market opportunities for etripamil and any future product candidates are smaller than the company estimates, its business may suffer.
• Coverage and adequate reimbursement may not be available for etripamil or any future product candidates, which could make it difficult for the company to gain market acceptance.
• If the company is unable to obtain and maintain patent protection for etripamil or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize drugs similar or identical to ours, and the company's ability to successfully commercialize its product candidates may be impaired.
• The company's future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for at least the next several years and believes its current funds will be sufficient to fund operations for at least the next 12 months. A Phase 3 study for AFib-RVR is planned, with patient enrollment anticipated in 2025.

Industry Context

The announcement highlights the competitive landscape of drug development, particularly in the cardiovascular space, with Milestone competing against larger pharmaceutical companies and generic treatments. The focus on patient-centered care and self-administered therapies reflects a broader trend in the healthcare industry.

Comparison to Industry Standards

• The document mentions competitors such as InCarda Therapeutics and Acesion Pharma, which are developing treatments for atrial fibrillation.
• The document references Rapiblyk (landiolol), an intravenous beta blocker approved for short-term ventricular rate reduction, as a competitor in the acute setting.
• The document cites ablation single-procedure success rates for PSVT are reported to be 91% to 96%.

Related Party Transactions

• The company has a license and collaboration agreement with Corxel, an entity affiliated with RTW Investments, LP, an existing shareholder of the company.
• The company entered into a Royalty Purchase Agreement and a Note Purchase Agreement with RTW Investments, LP and certain of its affiliates.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by changes in the company's financial performance and strategic decisions.
• Patients with PSVT and AFib-RVR could benefit from the potential approval and commercialization of etripamil.
• Suppliers and creditors may be impacted by the company's ability to meet its financial obligations.

Next Steps

• Awaiting FDA decision on CARDAMYST for PSVT by March 27, 2025.
• Initiating Phase 3 study for etripamil in AFib-RVR, with patient enrollment anticipated in 2025.
• Seeking regulatory approvals in other major markets through strategic partnerships.
• Exploring additional cardiovascular opportunities for the use of etripamil.
• Continuing to engage the FDA throughout the NDA review process.

Key Dates